Key companies, such as CSL Behring, Equillium, Biocon, and medac, are advancing their assets through late-stage graft versus host disease clinical trials, driving innovation in the graft versus ...

Graft versus host disease (GvHD) is an immune-driven disorder caused by a complex interplay between the donor's and recipient ...

The UnitedHealth Group division is taking Johnson & Johnson's Stelara — one of the most popular, best-known and most ...

Eli Lilly & Co. sees 60% sales increase for weight-loss drug in India, tapping into growing demand for anti-obesity solutions ...

Eli Lilly's weight-loss and diabetes drug Mounjaro, has seen sales in India jump 60 per cent between April and May. The ...

Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in emerging markets.

We have five products that will launch in the next 12-18 months. We recently launched Yesintek in the immunology space -- a ...

Biocon on Tuesday said it received approval from the government authorities for a generic diabetes medication – Liraglutide ...

Biocon Pharma Limited, a biopharmaceutical firm, on Tuesday said that drug regulator, Drugs Controller General of India under ...

Biotech firm Biocon on Tuesday said it has received approval from the government authorities for a generic diabetes ...

Biocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, ...